This is a randomized, placebo-controlled, study of SPI-62 in subjects with ACTH-dependent Cushing's syndrome caused by a non-adrenal tumor. Subjects will receive each of the following 2 treatments for 24 weeks: SPI-62 and matching placebo with the option of long-term extension.
This is a multicenter, randomized, placebo-controlled, Phase 2 study to evaluate the pharmacologic effect, efficacy, and safety of SPI-62 in subjects with ACTH-dependent Cushing's syndrome. Each subject who provides consent and meets all inclusion and exclusion criteria will participate in a screening period (Days -35 to -8), a baseline period (Days -7 to -1), and a treatment period (Day 1 of Week 1 to Day 168 ± 3 days of Week 24) and, the option of long-term extension. Subjects have the option to continue with the study on active study drug and return to the site every 3 months for blood tests and study drug dispensing. The visits may be conducted remotely if testing can be arranged.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
26
St. Joseph's Hospital and Medical Center - Barrow Neurological Institute (BNI) - Pituitary Center
Phoenix, Arizona, United States
Southwest General Healthcare Center
Fort Myers, Florida, United States
Mayo Clinic Cancer Center (MCCC) - Rochester
Rochester, Minnesota, United States
Washington University School of Medicine - Center for Advanced Medicine (CAM)
St Louis, Missouri, United States
Comprehensive and Interventional Pain Management Llp
Henderson, Nevada, United States
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Oregon Health & Science University (OHSU) - Northwest Pituitary Center
Portland, Oregon, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Medical University of Plovdiv
Plovdiv, Bulgaria
Clinical Center of Endocrinology and Gerontology, University Hospital of Endocrinology, Medical University Sofia (USHATE)
Sofia, Bulgaria
...and 2 more locations
Change from baseline in urinary HSD-1 ratio
The urinary HSD-1 ratio (tetrahydrocortisol + allotetrahydrocortisol ) / tetrahydrocortisone will be used as a biomarker of HSD-1 activity in liver. The primary analysis will include only subjects with Cushing's disease.
Time frame: Baseline to 6 weeks
Treatment emergent adverse events
Adverse events including clinically significant abnormal values on clinical laboratory evaluations, continuous glucose monitoring (CGM), 12-lead ECGs, vital signs measurements (including orthostatic vital sign measurements), physical examinations, and HPA and HPG axis biomarkers
Time frame: Baseline through 24 weeks of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.